CYC 202

Known as: CYC-202, CYC202 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
AIM Phase I study of seliciclib (CYC202, R-roscovitine), an inhibitor of cyclin-dependent kinases 2, 7 and 9, causing cell cycle… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in clinical trials, the purine roscovitine… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Apoptosis is essential for clearance of potentially injurious inflammatory cells and subsequent efficient resolution of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2005
Highly Cited
2005
(R)-Roscovitine (CYC202) is often referred to as a "selective inhibitor of cyclin-dependent kinases." Besides its use as a… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2004
Review
2004
CYC-202, the lead compound from the CYC-200 series of small-molecule cyclin-dependent kinase inhibitors, is under development by… (More)
Is this relevant?
Review
2003
Review
2003
Cyclin-dependent protein kinases (CDKs) are key regulators of the cell division cycle, whose various checkpoints proliferating… (More)
Is this relevant?
Review
2003
Review
2003
Aberrations in cell cycle progression occur in the majority of human malignancies. The main pathway affected is the… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
Review
2003
Review
2003
Aberrations in cell cycle control occurs in the majority of human malignancies due to inactivation of tumor suppressor gene Rb by… (More)
Is this relevant?
1994
1994
Effective therapies for advanced stages of hepatocellular carcinoma (HCC) have yet to be developed. We investigated how far a… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?